Cidnee Vaykovich
Direttore/Membro del Consiglio presso ChemioCare, Inc.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Nitin Kaushal | M | 58 |
Starton Therapeutics, Inc.
 Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017.
ChemioCare, Inc.
 ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | 6 anni |
| Eric Baum | M | 48 |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017.
ChemioCare, Inc.
ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | 6 anni |
| Kenneth Anderson | M | 72 |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | 4 anni |
| Pedro Lichtinger | M | 70 |
ChemioCare, Inc.
ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | - |
| Fotios Plakogiannis | M | 90 |
ChemioCare, Inc.
ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | - |
| Moses Dodo | M | 65 |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | 2 anni |
| Roman Rogol | M | - |
ChemioCare, Inc.
ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | - |
| Mohamad Hussein | M | - |
ChemioCare, Inc.
ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | - |
| Roy Waldon | M | - |
ChemioCare, Inc.
ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | - |
| Roy F. Waldron | M | 61 |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | 5 anni |
Grafico relazionale
Relazione in diverse aziende
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 10 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Cidnee Vaykovich
- Contatti personali
